Trump tariffs: Swiss companies target alternative export markets

Switzerland is experiencing significant economic contraction and anticipated job losses due to punitive 39% US tariffs, the highest in Europe, which are disproportionately affecting its critical medical technology sector. These tariffs are expected to either increase costs for US healthcare consumers and taxpayers or lead to a cessation of specialized medical device exports from Switzerland, as companies cannot absorb the added expense. In response to this market disruption, Switzerland is actively diversifying its trade relationships, having recently secured new agreements with India and Mercosur, and upgrading its deal with China, to mitigate reliance on the US market and maintain its export-driven economy, though long-term damage to US-Swiss business relations is expected.

Analysis

The US has imposed punitive 39% tariffs on Swiss imports, the highest in Europe, leading to significant economic contraction and anticipated job losses in Switzerland. This policy, announced on August 1st, disproportionately affects key Swiss industries, particularly the medical technology sector, which accounts for 17% of all Swiss exports to the US. Companies like MPS, a producer of specialized medical instruments, cannot absorb the tariff due to already thin margins, indicating increased costs for US patients and taxpayers.

While pharmaceuticals are currently exempt, a threatened 100% tariff on imported medicines poses a substantial future risk. The highly integrated and specialized nature of Swiss medical device manufacturing, as exemplified by MPS's CEO Gilles Robert, makes relocating production to the US extremely challenging, if not impossible. This could lead to Swiss companies ceasing exports of critical, unique medical devices to the US, potentially impacting patient access and supply.

In response, Switzerland is actively diversifying its trade relationships, having recently secured a deal with India and concluded an agreement with Mercosur. The country is also upgrading its trade deal with China, while its free trade with the EU, accounting for 50% of exports, remains intact. This strategic pivot aims to mitigate reliance on the US market and maintain Switzerland's export-driven economy amidst the "strongly negative" sentiment and "pessimistic" tone surrounding the US trade relations.

Despite the immediate economic damage, Swiss business leaders express a quiet confidence in their nation's resilience and ability to weather the storm by focusing on new markets. However, the long-term damage to the traditionally strong US-Swiss business relations and the perception of the US administration's global actions are significant, potentially altering future investment and partnership dynamics.

Key Decisions for Investors

• Monitor the ongoing US-Swiss trade negotiations and any potential escalation, particularly regarding the threatened 100% pharmaceutical tariff, as this could significantly impact healthcare sector investments.
• Evaluate the long-term implications of Switzerland's trade diversification efforts on global supply chains and market access for Swiss-made goods, which may shift investment opportunities.
• Assess the financial health and supply chain resilience of US healthcare providers and medical device distributors that rely on specialized Swiss imports, given the potential for increased costs or reduced availability.